Literature DB >> 1447634

Food-processing approaches to altering allergenic potential of milk-based formula.

Y H Lee1.   

Abstract

All the major cow milk proteins in their native states are potential allergens in infants with milk allergy. Heat treatment can reduce the antigenicity of whey proteins considerably, but it has virtually no effect on the antigenicity of casein. Infants allergic to milk still react to heat-denatured whey proteins. Therefore heat denaturation alone cannot produce a formula with low allergenicity. Enzyme hydrolysis reduces the antigenicity and allergenicity of protein. Partial hydrolysis produces hydrolysate consisting mainly of large peptides, whereas extensive hydrolysis produces hydrolysate containing a mixture of large and small peptides and free amino acids. Enzyme hydrolysis often produces bitter peptides and destroys the physical functionality of protein. When hydrolysate formula is made, casein or whey protein hydrolysate is ultrafiltered to remove large residual peptides. Certain amino acids are fortified to provide a balanced amino acid profile. The final formulation must comply with the recommendations of the Codex Alimentarius Commission (FAO/WHO) and the U.S. Infant Formula Act to provide adequate infant nutrition. Protein hydrolysate-based formula can be improved by further reducing the residual allergenicity, increasing the small peptide content, and improving the taste.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1447634     DOI: 10.1016/s0022-3476(05)81406-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition.

Authors:  A Høst; B Koletzko; S Dreborg; A Muraro; U Wahn; P Aggett; J L Bresson; O Hernell; H Lafeber; K F Michaelsen; J L Micheli; J Rigo; L Weaver; H Heymans; S Strobel; Y Vandenplas
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

2.  Differential growth patterns among healthy infants fed protein hydrolysate or cow-milk formulas.

Authors:  Julie A Mennella; Alison K Ventura; Gary K Beauchamp
Journal:  Pediatrics       Date:  2010-12-27       Impact factor: 7.124

3.  Early milk feeding influences taste acceptance and liking during infancy.

Authors:  Julie A Mennella; Catherine A Forestell; Lindsay K Morgan; Gary K Beauchamp
Journal:  Am J Clin Nutr       Date:  2009-07-15       Impact factor: 7.045

4.  The Risk Reduction Effect of a Nutritional Intervention With a Partially Hydrolyzed Whey-Based Formula on Cow's Milk Protein Allergy and Atopic Dermatitis in High-Risk Infants Within the First 6 Months of Life: The Allergy Reduction Trial (A.R.T.), a Multicenter Double-Blinded Randomized Controlled Study.

Authors:  Nicolaos Nicolaou; Rouzha Pancheva; Eva Karaglani; Mikaela Sekkidou; Miglena Marinova-Achkar; Simoneta Popova; Margarita Tzaki; Anastasia Kapetanaki; Nicoletta Iacovidou; Theodora Boutsikou; Zoi Iliodromiti; Vassiliki Papaevangelou; Olympia Sardeli; Paraskevi Xepapadaki; Evangelia Papathoma; Inge Thijs-Verhoeven; Urszula Kudla; Laurien H Ulfman; Anne Schaafsma; Yannis Manios
Journal:  Front Nutr       Date:  2022-05-25

5.  In vitro determination of the allergenic potential of egg white in processed meat.

Authors:  Sabine Hildebrandt; Larsen Schütte; Stefan Stoyanov; Günther Hammer; Hans Steinhart; Angelika Paschke
Journal:  J Allergy (Cairo)       Date:  2010-03-17

6.  Vegetable acceptance by infants: effects of formula flavors.

Authors:  Julie A Mennella; Janice M Kennedy; Gary K Beauchamp
Journal:  Early Hum Dev       Date:  2006-02-15       Impact factor: 2.079

7.  Flavor programming during infancy.

Authors:  Julie A Mennella; Cara E Griffin; Gary K Beauchamp
Journal:  Pediatrics       Date:  2004-04       Impact factor: 7.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.